Did Eli Lilly Just One-Up Novo Nordisk?
Eli Lilly and Novo Nordisk are fierce competitors in the diabetes and obesity markets. Each company is investing heavily to scale up production to meet demand.
Could Viking Therapeutics Become the Next Eli Lilly?
Eli Lilly's weight loss drugs are helping it conquer what may become a $100 billion market. Viking Therapeutics recently announced promising trial data for its weight loss candidate -- which works ...
Medicare allows coverage of Wegovy for heart patients
Older adults may now get Medicare coverage for the popular obesity drug Wegovy, so long as they're using it to cut their risk of serious heart problems and not for weight loss alone, according to n...
Eli Lilly and Novo can 'coexist for awhile' in the weight-loss drug space, says BMO's Evan Seigerman
Evan Seigerman, BMO Capital, joins 'Fast Money' to discuss BMO's inaugural GLP-1 conference.
Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?
Novo Nordisk's shares have benefited from some recent positive developments. The delay in the approval of donanemab has held back Eli Lilly's valuation.
A new study cites the health risks of intermittent fasting. Could it lift Ozempic sales?
A new medical study is raising concerns over whether intermittent fasting, a weight-loss method that's gained attention in recent years, could pose heart-health risks.
Should You Pick Eli Lilly Stock After A 4x Rise In Three Years?
Eli Lilly stock (NYSE: LLY) has seen phenomenal gains of 345% from levels of $170 in early January 2021 to around $755 now, vs. an increase of about 35% for the S&P 500 over this roughly three-year...
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
Last week's FDA approval of Rezdiffra in treating NASH is a huge milestone for Madrigal. Lilly and Novo Nordisk look much more impressive than Madrigal in most ways.
Wall Street's Favorite Growth Stocks? 7 Names That Could Make You Filthy Rich
Growth stocks are rising, offering stellar gains so far this year. The tech-heavy S&P 500 continues to post new highs, with investors shrugging off inflation concerns.
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead
Iovance Biotherapeutics just got a cell therapy for melanoma approved. The medicine will likely be very costly to make and deliver to patients.
Eli Lilly Just Had a Setback. Is Its Stock Still a Buy?
Eli Lilly is facing a major delay with its latest Alzheimer's program. Regulators are bringing in outside experts to review its approval request.
Lilly weight-loss drug Zepbound new US prescriptions surpass Wegovy for first time
Eli Lilly's powerful weight-loss drug Zepbound hit 77,590 new prescriptions in the U.S. for the week ending March 8, surpassing Novo Nordisk's rival obesity medicine Wegovy for the first time since...
Call of the Day: Eli Lilly
JP Morgan is hiking Eli Lilly's price target to $850. The Investment Committee debate it.
Can Eli Lilly Stock Double in 5 Years? Here's What It Would Take.
Eli Lilly has a huge opportunity in the anti-obesity market to generate tens of billions in revenue. The big battle could be over which company develops the best weight-loss drug.
Lilly (LLY) Partners Amazon to Deliver Drugs Like Zepbound
Eli Lilly (LLY) partners with Amazon Pharmacy to help deliver its obesity, migraine and diabetes drugs, including Zepbound.
Related Companies